Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20


Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis.

Chakravarthy M, Aung-Htut MT, Le BT, Veedu RN.

Sci Rep. 2017 May 9;7(1):1613. doi: 10.1038/s41598-017-01559-w.


A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.

Wang AP, Li XH, Yang YM, Li WQ, Zhang W, Hu CP, Zhang Z, Li YJ.

PLoS One. 2015 Jun 29;10(6):e0130806. doi: 10.1371/journal.pone.0130806. eCollection 2015.


Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.

Yu X, Yang L, Cairns MJ, Dass C, Saravolac E, Li X, Sun LQ.

Oncotarget. 2014 Oct 15;5(19):9039-48.


Delivery system for DNAzymes using arginine-modified hydroxyapatite nanoparticles for therapeutic application in a nasopharyngeal carcinoma model.

Chen Y, Yang L, Huang S, Li Z, Zhang L, He J, Xu Z, Liu L, Cao Y, Sun L.

Int J Nanomedicine. 2013;8:3107-18. doi: 10.2147/IJN.S48321. Epub 2013 Aug 14.


Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor-1α and hypoxia-inducible transcription factor-2α.

Ahmad A, Ahmad S, Malcolm KC, Miller SM, Hendry-Hofer T, Schaack JB, White CW.

Am J Respir Cell Mol Biol. 2013 Jul;49(1):78-85. doi: 10.1165/rcmb.2012-0107OC.


Inhibiting Plasmodium falciparum growth and heme detoxification pathway using heme-binding DNA aptamers.

Niles JC, Derisi JL, Marletta MA.

Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13266-71. doi: 10.1073/pnas.0906370106. Epub 2009 Jul 24.


RPS2: a novel therapeutic target in prostate cancer.

Wang M, Hu Y, Stearns ME.

J Exp Clin Cancer Res. 2009 Jan 12;28:6. doi: 10.1186/1756-9966-28-6.


DNAzymes and cardiovascular disease.

Benson VL, Khachigian LM, Lowe HC.

Br J Pharmacol. 2008 Jun;154(4):741-8. doi: 10.1038/bjp.2008.145. Epub 2008 May 5. Review.


Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM.

Am J Pathol. 2007 Oct;171(4):1079-88. Epub 2007 Aug 23. Review.


Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif.

Goodchild A, King A, Gozar MM, Passioura T, Tucker C, Rivory L.

Nucleic Acids Res. 2007;35(13):4562-72. Epub 2007 Jun 22.


Locked nucleoside analogues expand the potential of DNAzymes to cleave structured RNA targets.

Vester B, Hansen LH, Lundberg LB, Babu BR, Sørensen MD, Wengel J, Douthwaite S.

BMC Mol Biol. 2006 Jun 5;7:19.


A novel replicating circular DNAzyme.

Chen F, Wang R, Li Z, Liu B, Wang X, Sun Y, Hao D, Zhang J.

Nucleic Acids Res. 2004 Apr 28;32(8):2336-41. Print 2004.


RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Schubert S, Gül DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J.

Nucleic Acids Res. 2003 Oct 15;31(20):5982-92.


Electroporation-mediated delivery of catalytic oligodeoxynucleotides for manipulation of vascular gene expression.

Nunamaker EA, Zhang HY, Shirasawa Y, Benoit JN, Dean DA.

Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H2240-7. Epub 2003 Jul 24.


A ribozyme that ligates RNA to protein.

Baskerville S, Bartel DP.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9154-9. Epub 2002 Jun 20.


Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Khachigian LM.

J Clin Invest. 2000 Nov;106(10):1189-95. Review. No abstract available.


Supplemental Content

Support Center